Wockhardt Q2 FY27: consolidated PAT falls 11% YoY to ₹73 Cr as units abroad swing to loss
PAT -10.98% YoY · revenue +23.91% · margins compressing
₹969 Cr
+23.91% YoY
₹73 Cr
-10.98% YoY
7.45%
-2.8pp YoY
₹4.85
Wockhardt's consolidated (primary basis) revenue rose 23.9% YoY and 4.3% QoQ to ₹969 Cr, but consolidated net profit fell 11.0% YoY and 31.8% QoQ to ₹73 Cr, down from ₹107 Cr in Q1 FY27 and ₹82 Cr a year ago. That YoY profit decline despite strong topline growth is the headline: this was a margin-compression quarter, not a growth miss. The standalone (India) business tells almost the opposite story — standalone revenue jumped 52.6% YoY to ₹580 Cr and standalone PAT surged 85.2% YoY to ₹100 Cr, roughly in line with Q1's ₹107 Cr. The >3% divergence between the two bases is real and traceable: implied subsidiary-level profit (consolidated PAT minus standalone PAT) swung from +₹28 Cr a year ago and roughly breakeven last quarter to a ~₹27 Cr loss this quarter, even as implied subsidiary revenue held broadly flat (₹389 Cr vs ₹402 Cr YoY). The international/generics subsidiaries, not the India business, drove the miss.
Q2 FY-2027 vs prior quarters
The margin bridge confirms it: consolidated operating margin (EBITDA/revenue from operations) compressed to 17.85% from 22.76% a year ago and 20.67% last quarter — roughly a 490bps YoY and 280bps QoQ hit — while net margin (PAT/total income) fell to 7.45% from 10.21% YoY and 11.15% QoQ. The combined cost of materials and purchased goods (net of inventory movement) rose to about 35.2% of revenue from 29.8% a year ago, the single largest driver, with other expenses also running higher as a share of sales (27.1% vs 26.0% YoY). Finance costs (₹56 Cr) and depreciation (₹55 Cr) were both broadly flat YoY and QoQ, so the squeeze sits entirely in operating costs, not below-the-line items. One offsetting nuance: because non-controlling interest absorbed a ₹6 Cr loss this quarter (vs a ₹4 Cr profit a year ago and ₹1 Cr last quarter), PAT attributable to Wockhardt's own shareholders (₹79 Cr) held up far better than total PAT — down just ~1.3% YoY and basic EPS was effectively flat at ₹4.85 against ₹4.81 a year ago, even though total consolidated PAT fell double digits.
The stock went into the print at ₹1,895, down 10.5% over the past month of trading.
For context: revenue is at a 6-quarter high.
No consensus estimates for this specific quarter turned up in a search, and the comparison context carries no prior management guidance or concall read on record, so this cannot be graded against a Street number or a stated outlook — management gives no formal guidance on this print. Among the quarter's corporate developments, the company confirmed on August 10 that QIP proceeds utilization showed no deviation, consistent with continued capex/pipeline build: consolidated intangible assets under development rose to ₹1,743 Cr (from ₹1,708 Cr at FY26-end) and capital work-in-progress stood at ₹676 Cr. Separately, Wockhardt was fined ₹15 Cr by Customs on August 25 for API mis-classification; since the filing shows no exceptional item this quarter, that fine — if absorbed — would sit inside the regular expense lines rather than being called out, which the company has not done explicitly.
W1
Whether the implied subsidiary-level loss (~₹27 Cr this quarter vs +₹28 Cr a year ago) reverses next quarter
W2
Operating margin trajectory — compressed to 17.85% this quarter from 22.76% a year ago; watch if the materials/purchased-goods cost ratio (~35% of revenue vs ~30% a year ago) normalizes
W3
Commercialization/payback timeline on the ₹1,743 Cr consolidated intangible-assets-under-development pipeline, funded in part via the QIP whose proceeds utilization was confirmed on-track on August 10
Tax nets to zero both bases (current tax ₹4 Cr offset by deferred tax credit ₹4 Cr, consolidated). No exceptional items this quarter or in the Q2 FY26 base, so YoY/QoQ are on a clean basis. Consolidated PAT attributable to equity shareholders was ₹79 Cr (vs total ₹73 Cr) because non-controlling interest swung to a ₹6 Cr loss. Standalone and consolidated diverge sharply (+85% vs -11% YoY PAT) — flagged per basis rule. Document is clean, typed, unambiguous column headers.
Turnaround Holds — Profitability Momentum into Q2 on Watch
After Q1 FY27 delivered 26% revenue growth and a return to ₹107 Cr profit, Wockhardt faces the proof test: can the turnaround sustain? Analysts expect continued recovery at ₹2,175 target, but a ₹15 Cr customs penalty and margin pressures warrant watching on result day.
The Setup: Turnaround Traction into Q2
Wockhardt enters Q2 FY27 off a strong Q1 — revenue up 26% YoY to ₹929 Cr, with PAT swinging from a ₹108 Cr loss to a ₹107 Cr profit. The Street expects the recovery to hold. Analyst consensus targets sit at ₹2,175 on the back of sustained PAT growth through FY27 as the real valuation driver. The stock trades at ₹1,913.4 as of Oct 28, down 21% from ATH of ₹2,422.3 — inviting debate on whether the recovery is real or a head-fake worth a re-entry.
~₹950–980 Cr
Assuming sequential+YoY momentum from Q1's 26% growth trajectory (on-plan)
~₹110–130 Cr
Sustained double-digit return to profitability; margin hold at 22%+ critical
~22–24%
Q1 delivered 23.6% (₹219 Cr EBITDA on ₹929 Cr revenue). Watch for input cost/FX pressures
A strong Q2 print would show revenue in the ₹950–1,000 Cr band and PAT ₹110 Cr+, with EBITDA margin staying 22%+—confirming the turnaround is run-rate, not a blip. A weak print would be revenue below ₹920 Cr or PAT below ₹100 Cr—signalling momentum loss or margin headwinds despite top-line recovery. Watch for management commentary on API demand (especially post-customs scrutiny), any supply-chain pressure, and competitive pricing in key segments.
On Track for FY27 Guidance?
Wockhardt has not issued explicit full-year guidance, but the turnaround narrative is clear: divestiture of underperforming US generic assets and pivot to innovation-led, higher-margin segments are working. Q1 proved the business can grow top-line at 26% and hit mid-20s EBITDA margins while returning to profit. Q2 will test whether this is a new run-rate or a one-off bump. If management confirms or guides for low-to-mid-₹400 Cr PAT for FY27 (₹100+ per quarter), that validates the turnaround and the ₹2,000+ target. If they lower expectations or flag margin pressure, expect profit-taking.
Since Last Quarter: Filings Scan
Aug 25, 2026: Customs penalty adjudication—Commissioner of Customs, Nhava Sheva-II, imposed ₹5 Cr penalty + ₹10 Cr redemption fine under Sections 114(iii) and 125(1) of the Customs Act for alleged API misclassification. Company states no material impact on financials/operations and plans to challenge the order in appellate process. No production disruption signalled. Aug 10, 2026: QIP monitoring report—CRISIL confirmed no deviation in utilization of proceeds from the earlier QIP; capital deployment on-track. Aug 10, 2026: Antibiotic Academy—Company launched Wockhardt Antibiotic Academy, a CSR/patient-dialogue initiative on antimicrobial resistance; strategic/CSR, not financial. Routine: AGM held Aug 10; board approved Q1 results same day; trading window closure (Oct 1 to 48h post-announcement) standard for result season.
Three Things to Watch on November 2
1 · Revenue and growth rate
Is it ₹950–980 Cr (validating continued 20%+ growth)? Or does it drop to ₹900–920 Cr (suggesting market softness or margin-sacrifice pricing)? This is the headline growth number that validates the turnaround narrative.
2 · PAT and EBITDA margin
Expected ₹110–130 Cr PAT. If it lands here with EBITDA margin 22%+, the turnaround holds and ₹2,000+ is in play. If PAT < ₹100 Cr despite revenue growth, listen closely for margin-compression commentary—pricing pressure, input costs, or competitive intensity.
3 · FY27 PAT outlook and customs penalty clarity
Management will need to quantify the ₹15 Cr penalty impact on cash/working capital and provide an appeal timeline. Any FY27 PAT guidance (or revision) will move the needle. Also watch for API-demand color post-FDA/customs scrutiny and capex intensity for innovation assets.
Wockhardt's turnaround story got a real Q1 test and passed: 26% revenue growth, return to ₹107 Cr profit, and 23.6% EBITDA margin. Q2 will answer whether that's a durable new floor or a ceiling. Analysts are cautiously constructive at ₹2,175 target, betting FY27 delivers ₹400+ Cr PAT. The ₹15 Cr customs penalty is friction but not a deal-breaker if the company confirms zero operational impact and a clear appeal path. On Nov 2, watch for three things: revenue holding 20%+ growth, PAT above ₹110 Cr, and management's FY27 PAT confidence. A beat on all three could re-rate the stock toward ₹2,200+; a miss on revenue or margins will trigger a rethink of the turnaround thesis.